The antiviral nirmatrelvir, which is part of Paxlovid, was linked to a significant reduction in the risk for long COVID and post-acute death in patients with at least one risk factor for severe illness, according to researchers.Recent research has indicated that nearly 19 million adults in the United States may have long COVID. The condition has had a substantial impact on patients, many of whom
Traumatic deaths from motor vehicle crashes increase where large U.S. motorcycle rallies are held and a Harvard-led study suggests a corresponding, dramatic boost in organ donations and transplants.